Cartography Biosciences to Participate in Upcoming Investor Conferences

Barchart · 1d ago

Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that CEO and co-founder Kevin Parker, Ph.D., will participate in the following upcoming investor conferences:

  • BofA Healthcare Trailblazers Private Company Conference: September 23-24 in Boston
  • Needham Private Biotech and MedTech Company Virtual 1×1 Forum: October 13-14
  • Goldman Sachs Healthcare Private Company Conference: October 19 in New York City
  • Leerink Partners Biopharma Private Company Connect: October 19-20
  • UBS Global Biopharma Conference: November 16-17 in London

About Cartography Biosciences

Cartography Biosciences is advancing a differentiated oncology pipeline of antibody-based therapies designed to target tumors with unprecedented precision. The company’s ATLAS and SUMMIT discovery platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across healthy tissues alongside large-scale single-cell profiling of patient tumors. By combining petabyte-scale proprietary data, machine learning, and AI-driven biological insights, Cartography is identifying highly specific tumor targets and logic-gated target combinations to generate therapies engineered for maximal tumor selectivity and meaningful patient impact. The company’s lead program, CBI-1214, is a T-cell engager in development for colorectal cancer. CBI-1214 entered the clinic in early 2026 and is currently enrolling and treating patients in a phase 1 trial.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.